Abstracts
Abstract
Psychopharmacological cognitive enhancements could lead to a higher quality of life of healthy individuals with lower cognitive capacities, but the current regulatory framework does not seem to enable access to this group. This article discusses why Sen’s Capability Approach could open up such access, while two other modern social justice theories – utilitarianism and Rawls’ Justice as Fairness – could not. In short, the utilitarian approach is proven to be inadequate, due to practical reasons and having a low chance of real-world success. Rawls’ Justice as Fairness seems to be problematic because of conflicting stances that follow from his First Principle of Justice. The Capability Approach has the greatest chance of success in the context of these substances, because of arguments that can be identified under the banners of agency/self-respect and the way the public views those who take the capability path out of their poor situation. The article also discusses general and practical problems with psychopharmacological cognitive enhancement that should be addressed when writing new policy on this topic.
Keywords:
- smart drugs,
- psychopharmacological,
- cognitive enhancement,
- neuroethics,
- utilitarianism,
- justice as fairness,
- egalitarianism,
- capability approach
Résumé
Les améliorations cognitives psychopharmacologiques pourraient permettre d’améliorer la qualité de vie des personnes en bonne santé dont les capacités cognitives sont moindres, mais le cadre réglementaire actuel ne semble pas en permettre l’accès à ce groupe. Cet article explique pourquoi l’approche par les capacités de Sen pourrait permettre un tel accès, alors que deux autres théories modernes de justice sociale – l’utilitarisme et la justice en tant qu’équité de Rawls – ne le pourraient pas. En bref, l’approche utilitariste s’avère inadéquate, pour des raisons pratiques, et a peu de chances de réussir dans le monde réel. La justice équitable de Rawls semble problématique en raison des positions contradictoires qui découlent de son premier principe de justice. L’approche par les capacités a les plus grandes chances de succès dans le contexte de ces substances, en raison des arguments qui peuvent être identifiés sous les bannières de l’agence/du respect de soi et de la façon dont le public considère ceux qui prennent la voie des capacités pour sortir de leur mauvaise situation. L’article aborde également les problèmes généraux et pratiques liés à l’amélioration cognitive psychopharmacologique qui devraient être pris en compte lors de la rédaction d’une nouvelle politique sur ce sujet.
Mots-clés :
- drogues intelligentes,
- amélioration cognitive,
- psychopharmacologique,
- neuroéthique,
- utilitarisme,
- justice comme équité,
- égalitarisme,
- approche par les capacités
Appendices
Bibliography
- 1. Bostrom N, Roache R. Smart policy: Cognitive enhancement and the public interest. Contemporary Readings in Law and Social Justice. 2010;2(1).
- 2. Turner DC, Sahakian BJ. Neuroethics of cognitive enhancement. BioSocieties. 2006;1(1):113-123.
- 3. Cakic V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics. 2009;35(10):611-615.
- 4. Maturo A. Social justice and human enhancement in today’s bionic society. Salute E Società. 2012;IX(2):15-28.
- 5. Franke A, Bagusat C, Rust S, Engel A, Lieb K. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. European Archives of Psychiatry and Clinical Neuroscience. 2014;264(S1):83-90.
- 6. Moskal J, Burch R, Burgdorf J, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opinion on Investigational Drugs. 2014;23(2):243-254.
- 7. Turner D, Robbins T, Clark L, Aron A, Dowson J, Sahakian B. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003;165(3):260-269.
- 8. Maier L, Ferris J, Winstock A. Pharmacological cognitive enhancement among non-ADHD individuals—A cross-sectional study in 15 countries. International Journal of Drug Policy. 2018;58:104-112.
- 9. British Medical Association. Boosting your brainpower: ethical aspects of cognitive enhancements. 2007.
- 10. Maslen H, Douglas T, Cohen Kadosh R, Levy N, Savulescu J. The regulation of cognitive enhancement devices: extending the medical model. Journal of Law and the Biosciences. 2014;1(1):68-93.
- 11. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702-705.
- 12. Dubljevic V. Toward a legitimate public policy on cognition-enhancement drugs. AJOB Neuroscience. 2012;3(3):29-33.
- 13. Dubljevic V. Principles of justice as the basis for public policy on psychopharmacological cognitive enhancement. Law, Innovation and Technology. 2012;4(1):67-83.
- 14. Partridge B. A bubble of enthusiasm: how prevalent is the use of prescription stimulants for cognitive enhancement? In: Hildt E, Franke A, editors, Cognitive Enhancement An Interdisciplinary Perspective. Dordrecht: Springer; 2013. p. 39-47.
- 15. Dunlop M, Savulescu J. Distributive justice and cognitive enhancement in lower, normal intelligence. Monash Bioethics Review. 2014;32(3-4):189-204.
- 16. Trappenburg MJ. Defining the medical sphere. Cambridge Quarterly of Healthcare Ethics. 1997;6(4):416-434.
- 17. Walzer M. Spheres of Justice: A Defense of Pluralism and Justice. New York: Basic; 1983.
- 18. Siep L. Normative aspects of the human body. The Journal of Medicine and Philosophy. 2003;28(2):171-185.
- 19. Sofuoglu M, DeVito E, Waters A, Carroll K. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452-463.
- 20. Ressler K, Rothbaum B, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinctionof fear. Archives of General Psychiatry. 2004;61(11):1136-1144.
- 21. Guastella A, Richardson R, Lovibond P, et al. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry. 2008;63(6):544-549.
- 22. Farah M, Illes J, Cook-Deegan R, et al. Neurocognitive enhancement: what can we do and what should we do? Nature Reviews Neuroscience. 2004;5(5):421-425.
- 23. Bagot K, Kaminer Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction. 2014;109(4):547-557.
- 24. de Jongh R, Bolt I, Schermer M, Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience & Biobehavioral Reviews. 2008;32(4):760-776.
- 25. Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Science and Engineering Ethics. 2009;15(3):311-341.
- 26. Gladstone D, Black S. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2000;27(2):97-105.
- 27. Hylin M, Brenneman M, Corwin J. Noradrenergic antagonists mitigate amphetamine-induced recovery. Behavioural Brain Research. 2017;334:61-71.
- 28. Kortekaas-Rijlaarsdam A, Luman M, Sonuga-Barke E, Oosterlaan J. Does methylphenidate improve academic performance? A systematic review and meta-analysis. European Child & Adolescent Psychiatry. 2019;28(2):155-164.
- 29. de Jongh R. Overclocking the brain? The potential and limitations of cognitionenhancing drugs. In: ter Meulen R, Mohammed A, Hall W, editor, Rethinking Cognitive Enhancement. Oxford University Press; 2017. p. 37-56.
- 30. Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research. 2010;62(3):187-206.
- 31. Smith M, Farah M. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin. 2011;137(5):717-741.
- 32. Schermer M, Bolt I, de Jongh R, Olivier B. The future of psychopharmacological enhancements: expectations and policies. Neuroethics. 2009;2(2):75-87.
- 33. Gibbs S, D’Esposito M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology. 2005;180(4):644-653.
- 34. Mattay V, Goldberg T, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proceedings of the National Academy of Sciences. 2003;100(10):6186-6191.
- 35. Ilieva I, Boland J, Farah M. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2013;64:496-505.
- 36. Bentham J. An Introduction to the Principles of Morals and Legislation. University of London: The Athlone Press; 1970.
- 37. Buchanan A, Brock DW, Daniels N, Wikler D. From Chance to Choice: Genetics and Justice. Cambridge University Press; 2001.
- 38. Boorse C. Health as a theoretical concept. Philosophy of science. 1977;44(4):542-73.
- 39. Savulescu J. Justice, fairness, and enhancement. Annals of the New York Academy of Sciences. 2006;1093(1):321-338.
- 40. Sandberg A, Savulescu J. The social and economic impacts of cognitive enhancement. In: Savulescu J, Meulen R, Kahane G, ed. by. Enhancing Human Capacities. Oxford: Blackwell Publishing; 2011.
- 41. Herrnstein RJ, Murray C. The Bell Curve: Intelligence and Class Structure in American Life. New York: The Free Press; 1994.
- 42. Rawls J. Justice as fairness. The Philosophical Review. 1958;67(2):164-194.
- 43. Rawls J. Justice as fairness: political not metaphysical. Philosophy & Public Affairs. 1985;13(3):223-251.
- 44. Glannon W. Psychopharmacological enhancement. Neuroethics. 2008;1(1):45-54.
- 45. Dubljevic V. Autonomy and justice in neuroethics of cognitive enhancement. Thesis, Faculty of Philosophy and History, University of Stuttgart; 2014.
- 46. Beyer C, Staunton C, Moodley K. The implications of methylphenidate use by healthy medical students and doctors in South Africa. BMC Medical Ethics. 2014;15(1).
- 47. Rawls J. A Theory of Justice (Original ed.). Cambridge, Mass.: Belknap Press of Harvard University Press; 1971.
- 48. Sen A. The Idea of Justice. Cambridge, Mass.: Belknap Press of Harvard University Press; 2009.
- 49. Robeyns I. The capability approach: a theoretical survey. Journal of Human Development. 2005;6(1):93-117.
- 50. Nam J. Biomedical enhancements as justice. Bioethics. 2015;29(2):126-132.
- 51. Robeyns I, Fibieger Byskov M. The capability approach. Stanford Encyclopedia of Philosophy; (Winter 2020 Edition), Zalta EN, editor; 14 Apr 2011 (rev. 10 Dec 2020).
- 52. Nussbaum MC. Women and Human Development: The Capabilities Approach (Vol. 3). Cambridge: Cambridge University; 2001.
- 53. Harris J. Chemical cognitive enhancement: is it unfair, unjust, discriminatory, or cheating for healthy adults to use smart drugs. In: Illes J, Sahakian B, ed. by. Oxford Handbook of Neuroethics. Oxford: Oxford University Press; 2011. p. 265-272.
- 54. Moreno J. Mind wars: Brain research and national defense. New York: Dana Press; 2006.
- 55. Drabiak-Syed K. Sleep Deprived Physicians Considering Modafinil: Using a Controlled Substance for Cognitive Enhancement Gambles with Differential Drug Responses and Violates Ethical and Legal Duties Against Physician Impairment. DePaul J. Health Care L. 2010; 13:339-366.
- 56. Linssen A, Sambeth A, Vuurman E, Riedel W. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. The International Journal of Neuropsychopharmacology. 2014;17(06):961-977.
- 57. Lakhan S, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain and Behavior. 2012;2(5):661-677.
- 58. Grant J, Redden S, Lust K, Chamberlain S. Nonmedical Use of Stimulants Is Associated With Riskier Sexual Practices and Other Forms of Impulsivity. Journal of Addiction Medicine. 2018;12(6):474-480.
- 59. Lavazza A. A Rawlsian Version of the Opportunity Maintenance Thesis. The American Journal of Bioethics. 2016;16(6):50-52.
- 60. Garasic M, Lavazza A. Performance enhancement in the workplace: why and when healthy individuals should disclose their reliance on pharmaceutical cognitive enhancers. Frontiers in Systems Neuroscience. 2015;9.